Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 18, Issue 2, 2001, Pages 201-264

  DeFelippis, M R ^a   Chance, R E ^a   Frank, B H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetes treatment; Insulin; Insulin analogs; Ligand binding; Pharmacodynamics; Pharmacokinetics; Physicochemical properties; Self association; Structure

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; PROINSULIN;

AMINO ACID ANALYSIS; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG PURITY; DRUG STRUCTURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIGAND BINDING; NONHUMAN; PHARMACEUTICAL ENGINEERING; PHYSICAL CHEMISTRY; REVIEW; TECHNOLOGY; X RAY CRYSTALLOGRAPHY;

EID: 0035032976     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v18.i2.30     Document Type: Review

References (324)

1. The internal secretion of the pancreas
2. Structure of rhombohedral 2 zinc insulin crystals
3. Insulin: The structure in the crystal and its reflection in chemistry and biology
4. The structure of 2Zn pig insulin crystals at 1.5Å resolution
5. The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma
6. Insulin today
7. Role of zinc in insulin biosynthesis
8. The role of assembly in insulin's biosynthesis
9. Receptor triggering and receptor regulation: Structure-activity relationships from the receptor's point of view
10. Insulin action 1991
11. Molecular determinants of insulin action
12. Insulin secretion in vivo
13. From receptor to transporter: Insulin signalling to glucose transport
14. Insulin agonist therapy: A challenge for the 1990s
15. Improving insulin therapy: Achievements and challenges
16. Insulin analogs with improved pharmacokinetic profiles
17. Normalization of plasma insulin profiles in diabetic subjects with programmed insulin delivery
18. The pharmacokinetic basis of insulin therapy in diabetes mellitus
19. Towards more physiological insulin therapy in the 1990s: A comment
20. Insulin chemistry and pharmacokinetics
21. Control of blood sugar in insulin-dependent diabetes: Comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion and intensified conventional insulin therapy
22. Glycemic control in insulin-dependent diabetes mellitus comparison of outpatient intensified conventional therapy with continuous subcutaneous insulin infusion
23. Insulin treatment: A decade of change
24. Subcutaneous insulin delivery: Present status
25. The physiological replacement of insulin: An elusive goal
26. How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes
27. Pharmacokinetics of continuous subcutaneous insulin infusion
28. Lessons from studies of insulin pharmacokinetics
29. Devices for insulin administration
30. The pursuit of perfect control in diabetes
31. Alternative insulin delivery systems: How demanding should the patient be?
32. Human insulin and its modifications
33. Future trends in insulin therapy: Clinical implications of novel insulin analogues and nasal administration of insulin
34. Approaches to insulin analogues
35. New insulins and other possible therapeutic approaches
36. Insulin formulation and delivery
37. Pharmacokinetic considerations of new insulin formulations and routes of administration
38. Novel methods of insulin delivery: An update
39. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
40. The absence of a glycemic threshold for the development of long-term complications: The perspective of the diabetes control and complications trial
41. The biochemistry of the complications of diabetes mellitus
42. Meticulous control of diabetes: Benefits, risks, and precautions
43. Expression in Escherichia coli of chemically synthesized genes for human insulin
44. Synthesis and biological activity of seventeen analogues of human insulin
45. Insulin chemistry
46. Semisynthetic des-(B27-B30)-insulins with modified B26-tyrosine
47. Enzyme-assisted semisynthesis of shortened B26-modified insulins
48. Insulin chemistry today: From the first synthesis to tailor-made derivatives and biosynthetic analogues
49. Studies on crystalline insulin V The distribution of nitrogen in crystalline insulin
50. Chemistry of insulin
51. Receptor-binding region of insulin
52. Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor
53. Disposition of the phenylalanine B25 side chain during insulin-receptor and insulin-insulin interactions
54. Importance of the character and configuration of residues B24, B25, and B26 in insulin-receptor interactions
55. Importance of aliphatic side-chain structure at positions 2 and 3 of the insulin A chain in insulin-receptor interactions
56. 13C-isotope-aided 2D-NMRstudies of [PheB24→Gly] insulin with implications for receptor recognition
57. The A14 position of insulin tolerates considerable structural alterations with modest effects on biological behavior of the hormone
58. Semisynthetic insulin analogues modified in positions B24, B25, and B29
59. Self-association of insulin: Its pH dependence and effect of plasma
60. Insulin's structure as a modified and monomeric molecule
61. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer
62. 1H NMR assignments for human insulin
63. 1H NMR studies of monomeric insulin
64. 1H NMR spectrum of the native human insulin monomer
65. Conformational dynamics of insulin in solution. Circular dichroic studies
66. Changes in secondary structure follow the dissociation of human insulin hexamers: A circular dichroism study
67. Structure-function relationships in the free insulin monomer
68. Conformational flexibility of aqueous monomeric and dimeric insulin: A molecular dynamics study
69. X-ray analysis of the single chain B29-A1 peptide-linked insulin molecule. A completely inactive analogue
70. Insulin analogs with modifications in the β-turn of the B-chain
71. Receptor binding redefined by a structural switch in a mutant human insulin
72. Dynamics of a monomeric insulin analogue: Testing the molten-globule hypothesis
73. An insulin with the native sequence but virtually no activity
74. Conformation of proinsulin. A comparison of insulin and proinsulin self-association at neutral pH
75. Differences in the nature of the interaction of insulin and proinsulin with zinc
76. Zinc binding, circular dichroism, and equilibrium sedimentation studies on insulin (bovine) and several of its derivatives
77. Polymerization pattern of insulin at pH 7.0
78. Conformational stability and self-association of zinc-free bovine insulin at neutral pH
79. The self-association of zinc-free bovine insulin. A single model based on interactions in the crystal that describes the association pattern in solution at pH 2, 7, and 10
80. The self-association of zinc-free bovine insulin. Four model patterns and their significance
81. Insulin association in neutral solutions studied by light scattering
82. The influence of ionic strength and pH on the aggregation properties of zinc-free insulin studied by static and dynamic laser light scattering
83. Concentration difference spectra in the dimerization of insulin
84. The thermodynamics of bovine and porcine insulin and proinsulin association determined by concentration difference spectroscopy
85. Insulin-metal ion interactions: The binding of divalent cations to insulin hexamers and tetramers and the assembly of insulin hexamers
86. The self-association of zinc-free human insulin and insulin analogue B 13-glutamine
87. Insulin and proinsulin conformation in solution
88. Self-association of insulin and the role of hydrophobic bonding: A thermodynamic model of insulin dimerization
89. Self-association of des-(B26-B30)-insulin
90. The crystal structure of deshexapeptide (B25-B30) insulin at 0.25 nm resolution
91. Crystal structure of desheptapeptide (B24-B30) insulin at 1.6 Å resolution: Implications for receptor binding
92. Crystalline insulin
93. Structural stability in the 4-zinc human insulin hexamer
94. 6 insulin/phenol complex
95. X-ray crystallographic studies on hexameric insulins in the presence of helix-stabilizing agents, thiocyanate, methylparaben, and phenol
96. 3 human insulin hexamer
97. Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin, and miniproinsulin
98. Phenol-promoted structural transformation of insulin in solution
99. Cooperativity and intermediate states in the T→R-structural transformation of insulin
100. Zinc coordination, asymmetry, and allostery of the human insulin hexamer
101. Characterization of the R-state insulin hexamer and its derivatives: The hexamer is stabilized by heterotropic ligand binding interactions
102. 6 allosteric transition of the Co(II)-substituted insulin hexamer
103. The allosteric transition of the insulin hexamer is modulated by homotropic and heterotropic interactions
104. Spectroscopic signatures of the T to R conformational transition in the insulin hexamer
105. 6 insulin hexamer
106. Role of B13 Glu in insulin assembly. The hexamer structure of recombinant mutant (B13 Glu → Gln) insulin
107. Structure of insulin in 4-zinc insulin
108. B29-human insulin
109. finsulin
110. Molecular structure of insulin: The insulin monomer and its assembly
111. Testing of insulin hexamer-stabilizing ligands using theoretical binding, microcalorimetry, and nuclear magnetic resonance (NMR) line broadening techniques
112. The use of microcalorimetry to measure thermodynamic parameters of the binding of ligands to insulin
113. Hierarchical modeling of phenolic ligand binding to 2Zn-insulin hexamers
114. Simulation of a complex protein structural change: The T→R transition in the insulin hexamer
115. Half-site, reactivity, negative cooperativity, and positive cooperativity: Quantitative considerations of a plausible model
116. Plasma insulin glucose profiles in normal, obese, and diabetic persons
117. "Normal" insulin secretion: The goal of artificial insulin delivery systems?
118. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects
119. Insulin preparations with prolonged effect
120. Insulin rapitard and insulin actrapid
121. Protamine insulinate
122. Studies on insulin with protamine
123. Purification and analysis of the major components of chum salmon protamine contained in insulin formulations using high-performance liquid chromatography
124. Crystalline protamine insulin
125. Structure of porcine insulin cocrystallized with clupeine-Z
126. Crystalline and amorphous insulin-zinc compounds with prolonged action
127. The lente insulins
128. B29-human insulin with ultralente properties
129. Mixtures of human intermediate and human regular insulin in type 1 diabetic patients
130. A comparison of the pharmacokinetics and metabolic effects of human regular insulin and NPH insulin mixtures
131. Premixed insulin at a ratio 3/7 and regular + isophane insulins at mixing ratios from 2/8 to 4/6 achieve the same metabolic control
132. Reversible absorption of soluble hexameric insulin onto the surface of insulin crystals cocrystallized with protamine: An electrostatic interaction
133. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures
134. Mixtures of intermediate-acting insulin (NPH and Lente) with regular insulin: An update
135. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins
136. Crystalline insulin
137. Recrystallized insulin for diabetic patients with insulin allergy
138. Heterogeneity of crystalline insulin
139. Isolation and properties of proinsulin, intermediate forms, and other minor components from crystalline bovine insulin
140. Clinical aspects of insulin-antigenicity
141. The immunogenicity of insulin preparations
142. The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins
143. Immunogenicity of insulin. A review
144. Effect of insulin antibodies and their kinetic characteristics on plasma free insulin dynamics in patients with diabetes mellitus
145. Immunogenicity and allergenic potential of animal and human insulins
146. Synthese der insulinketten und ihre kombination zu insulinaktiven präparaten
147. The synthesis of the insulin chains and their combination to biologically active material
148. Total synthesis of crystalline insulin
149. Semi-synthesis of human insulin by trypsin-catalysed replacement of Ala-B30 by Thr in porcine insulin
150. Human insulin (Novo): Chemistry and characteristics
151. Chemical, physical, and biological properties of biosynthetic human insulin
152. Human insulin from recombinant DNA technology
153. The production of human proinsulin and its transformation to human insulin and C-peptide
154. Research, development, production, and safety of biosynthetic human insulin
155. Secretion and processing of insulin precursors in yeast
156. Biosynthesis of human insulin in yeast via single-chain precursors
157. Postbiosynthesis modification: Human growth hormone and insulin precursors
158. Pharmacokinetics of biosynthetic human insulin and characteristics of its effect
159. Clinical pharmacologic studies with human insulin (recombinant DNA)
160. Absorption kinetics of semisynthetic human insulin and biosynthetic (recombinant DNA) human insulin
161. Effects of physical exercise on insulin absorption in insulin-dependent diabetics. A comparison between human and porcine insulin
162. Biosynthetic human insulin improves postprandial glucose excursions in type 1 diabetes
163. The crystal structures of three non-pancreatic human insulins
164. Monomeric insulins and their experimental and clinical implications
165. The biological properties of human insulin
166. A comparison of the activity and disposal of semi-synthetic human insulin and porcine insulin in normal man by the glucose clamp technique
167. Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man
168. Human insulin: Much ado about one amino acid?
169. Absorption of soluble and isophane semi-synthetic human and porcine insulin in insulin-dependent diabetic subjects
170. Clinical pharmacology of human insulin
171. Time-action characteristics of regular and NPH insulin in insulin-treated diabetics
172. Absorption kinetics and biological effects of subcutaneously injected insulin preparations
173. The pharmacokinetics of subcutaneous regular insulin in type I diabetic patients: Assessment using a glucose clamp technique
174. Free insulin profiles in insulin-dependent diabetics treated with one or two insulin injections per day
175. Absorption kinetics and action profiles of intermediate acting human insulins
176. The action profiles of human NPH insulin preparations
177. Pharmacokinetics of long-acting (ultralente) insulin preparations
178. Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling
179. A comparison of human ultralente- and lente-based twice-daily injection regimens
180. Twice-daily humulin ultralente insulin decreases morning fasting hyperglycemia
181. Structural and morphological characterization of ultralente insulin crystals by atomic force microscopy: Evidence of hydrophobically driven assembly
182. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus
183. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics
184. The importance of the time interval between insulin injection and breakfast in determining postprandial glycaemic control - A comparison between human and porcine insulin
185. Timing between the subcutaneous administration of insulin and consumption of a carbohydrate-rich meal
186. The absorption of subcutaneously injected short-acting soluble insulin: Influence of injection technique and concentration
187. Insulin pharmacokinetics
188. Qualitative aspects of subcutaneous insulin absorption
189. Effect of raising injection-site skin temperature on isophane (NPH) insulin crystal dissociation
190. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique
191. Absorption of NPH (isophane) insulin in resting diabetic patients: Evidence for subcutaneous injection in the thigh as the preferred site
192. B29]-human insulin analogue
193. Monomeric insulins obtained by protein engineering and their medical implications
194. Altering the association properties of insulin by amino acid replacement
195. Chemical stability of insulin-3. Influence of excipients, formulation, and pH
196. Toward understanding insulin fibrillation
197. 2+
198. Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients
199. Human insulin analogs with rapid onset and short duration of action
200. Synthesis of a fast-acting insulin based on structural homology with insulin-like growth factor I
201. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I
202. Insulin analogues
203. Discovery and development of insulin lispro
204. Fast acting human insulin analogues with single amino acid deletion in the B-chain
205. Physical stabilization of insulin by glycosylation
206. The relation of conformation and association of insulin to receptor binding: X-ray and circular-dichroism studies on bovine and hystricomorph insulins
207. Near-ultraviolet tyrosyl circular dichroism of pig insulin monomers, dimers, and hexamers. Dipole-dipole coupling calculations in the monopole approximation
208. 1H NMR assignments for the aromatic region of several biologically active, monomeric insulins including native human insulin
209. 13C labeling with application to protein design
210. Mutations at the dimer, hexamer, and receptor-binding surfaces of insulin independently affect insulin-insulin and insulin-receptor interactions
211. Comparison of the dynamics of an engineered insulin monomer and dimer by acid-quenched amide proton exchange
212. Proton nuclear magnetic resonance study of the B9(Asp) mutant of human insulin sequential assignment and secondary structure
213. Three-dimensional solution structure of an insulin dimer. A study of the B9(Asp) mutant of human insulin using nuclear magnetic resonance, distance geometry and restrained molecular dynamics
214. High-resolution structure of an engineered biologically potent insulin monomer, B16 Tyr → His, as determined by nuclear magnetic resonance spectroscopy
215. The high resolution solution structure of the insulin monomer determined by NMR
216. Solution structure of the superactive monomeric des-[Phe(B25)] human insulin mutant: Elucidation of the structural basis for the monomerization ofdes-[Phe(B25)] insulin and the dimerization of native insulin
217. Designing insulin for diabetes therapy by protein engineering
218. Mutant insulin crystal packing
219. Molecular recognition in insulin assembly
220. Insulin assembly: Its modification by protein engineering and ligand binding
221. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 Pro → Asp insulin analogues
222. Crystallization and preliminary crystallographic analyses of human insulin mutant B9 (Ser→Asp) in different aggregation forms
223. B29-insulin: Dissociation of a protein-ligand complex
224. B29-insulin hexamers: A comparison study
225. Self-association properties of monomeric insulin analogs under formulation conditions
226. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM
227. B29human insulin analog and regular human insulin in the correction of incidental hyperglycemia
228. Improved mealtime treatment of diabetes mellitus using an insulin analogue
229. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus
230. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment
231. Metabolic efficacy of preprandial administration of Lys(B28),Pro(B29) human insulin analog in IDDM-patients
232. Are presently available insulin analogues clinically beneficial?
233. Insulin lispro
234. Pharmacokinetics and glucodynamics of insulin lispro
235. Clinical studies on insulin lispro
236. From insulin to insulin analogs: Progress in the treatment of type 1 diabetes
237. Insulin analogues and their potential in the management of diabetes mellitus
238. A superactive insulin: [B10-aspartic acid]insulin (human)
239. Equivalent in vivo biological activity of insulin analogues and human insulin despite different in vitro potencies
240. Scintigraphic studies in rats, kinetics of insulin analogues covering wide range of receptor affinities
241. In vitro and in vivo potency of insulin analogues designed for clinical use
242. Metabolic effects of monomeric insulin analogues of different receptor affinity
243. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake
244. Preclinical studies of rapid-acting insulin analogues
245. The potential immunogenicity of human insulin and insulin analogues in a transgenic mouse model
246. Molecular actions of insulin analogues
247. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency
248. Immunological effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin
249. Modifications in the BI0 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor
250. B29 insulin
251. Preclinical studies on insulin lispro
252. Preclinical safety pharmacology studies on the rapid-acting insulin analogue insulin aspart
253. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin
254. B29-human insulin - Assessed in a conscious pig model
255. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric analogue [Lys(B28), Pro(B29)] in IDDM
256. Prandial glycemia after a carbohydrate-rich meal in type I diabetic patients: Using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin
257. [Lys(B28), Pro(B29)]-human insulin: Effect of injection time on postprandial glycemia
258. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic β-cell function
259. Recombinant DNA derived monomeric insulin analogue: Comparison with soluble human insulin in normal subjects
260. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans
261. B28) in subjects
262. Clinical results of phase I studies with insulin analogues
263. Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes
264. B28) on meal-related plasma glucose excursions in type I diabetic subjects
265. Action profiles of fast onset insulin analogues
266. Action profile of the rapid acting insulin analogue: Human insulin B28Asp
267. Action profile of rapid-acting human insulin analogues
268. Time-action profile of the insulin analogue B28Asp
269. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28Asp
270. Insulin kinetics and dynamics in insulin-dependent diabetic patients after injections of human insulin or insulin analogues X14 and X14 + Zn
271. Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp)
272. Glycaemic control in IDDM patients during one day with injection of human insulin or the insulin analogues insulin X14 and insulin X14 (+Zn)
273. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen
274. Improved glycemic control with insulin aspart. A multicenter randomized double-blind crossover trial in type 1 diabetic patients
275. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart
276. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers
277. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes
278. Long-acting insulin analogs
279. Design of novel insulins with changed self-association and ligand binding properties
280. Studies on long-acting insulin: Crystal structure of Arg-B31 human insulin at 2.0Å resolution
281. Treatment of NIDDM with insulin agonists or substitutes
282. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience
283. Receptor binding and biological potency of several split forms (conversion intermediates) of human proinsulin
284. Hypoglycemic potency and metabolic clearance rate of intravenously administered human proinsulin and metabolites
285. Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin
286. Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain
287. Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30
288. In vitro activity of biosynthetic human diarginylinsulin
289. Di-arg insulin, an insulin analogue: Metabolic action on glucose and lipid metabolism in diabetic patients
290. Intravenous infusion of diarginylinsulin, an insulin analogue: Effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients
291. Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23 and B30
292. New insulin preparations with prolonged action profiles: A21-modified arginine insulins
293. Controlling insulin bioavailability by crystal contact engineering
294. 6 insulin hexamers
295. NovoSol Basal: Pharmacokinetics of a novel soluble long acting insulin analogue
296. Comparison of the pharmacokinetics of Gly(A21)-Arg(B31,B32)-human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique
297. Pharmacokinetics of a "long-acting" human insulin analogue (HOE 901) in healthy subjects
298. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE901) in muscle cells
299. The long-acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin
300. Albumin binding of insulins acylated with fatty acids: Characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo
301. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs
302. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs
303. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304
304. Crystal structure of a prolonged-acting insulin with albumin-binding properties
305. Basal activity profiles of NPH and [Nε-palmitoyl Lys (B29)] human insulins in subjects with IDDM
306. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue
307. 2+ ions
308. The cobalt(III)-insulin hexamer is a prolonged-acting insulin prodrug
309. Action profile of cobalt (III)-insulin. A novel principle of protraction of potential use for basal insulin delivery
310. Nighttime insulin kinetics and glycemic control in type 1 diabetic patients following administration of an intermediate-acting lispro preparation
311. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin
312. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients
313. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation
314. Insulin aspart in a 30/70 premixed formulation
315. Time-action profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo
316. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes
317. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
318. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
319. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
320. The new era of biotech insulin analogues
321. Iontophoresis of monomeric insulin analogues in vitro: Effects of insulin charge and skin pretreatment